Key Highlights

Risk & Performance

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Phase 1

3(60.0%)

Phase 3

2(40.0%)

5Total

Phase 1(3)

Phase 3(2)

Loading network data...

Showing 5 of 5 trials

This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.

Role: lead

Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.

Role: lead

Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients

Role: lead

Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients

Role: lead

A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC

Role: lead

All 5 trials loaded